156 related articles for article (PubMed ID: 3092311)
1. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
Pirofsky B
Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of a new pH 4.25 intravenous immunoglobulin preparation (gamimune-N).
Pirofsky B
J Infect; 1987 Jul; 15 Suppl 1():29-37. PubMed ID: 3117898
[TBL] [Abstract][Full Text] [Related]
3. Safety and patient acceptability of intravenous immune globulin in 10% maltose.
Ochs HD; Buckley RH; Pirofsky B; Fischer SH; Rousell RH; Anderson CJ; Wedgwood RJ
Lancet; 1980 Nov; 2(8205):1158-9. PubMed ID: 6107768
[TBL] [Abstract][Full Text] [Related]
4. Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens.
Hill HR; Bathras JM
Rev Infect Dis; 1986; 8 Suppl 4():S396-400. PubMed ID: 3092306
[TBL] [Abstract][Full Text] [Related]
5. Decreased incidence of adverse infusion reactions in hypogammaglobulinemic children receiving low pH intravenous immunoglobulin.
Roberton DM; Hosking CS; Efthimiou H; Wright S; Upton H; Colgan T; Hartman L; Schiff P
Aust N Z J Med; 1987 Oct; 17(5):495-500. PubMed ID: 3446162
[TBL] [Abstract][Full Text] [Related]
6. Three generations of immunoglobulin G preparations for clinical use.
McCue JP; Hein RH; Tenold R
Rev Infect Dis; 1986; 8 Suppl 4():S374-81. PubMed ID: 3092303
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
[TBL] [Abstract][Full Text] [Related]
8. Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25.
Schwartz RS
Am J Med; 1987 Oct; 83(4A):46-51. PubMed ID: 3118708
[TBL] [Abstract][Full Text] [Related]
9. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
11. Use of a new, low-pH immunoglobulin G preparation during episodes of bacteremia in the rat.
Emerson TE; Collins MS; Budinger MD
Rev Infect Dis; 1986; 8 Suppl 4():S409-19. PubMed ID: 3092308
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.
Garbett ND; Currie DC; Cole PJ
Clin Exp Immunol; 1989 Apr; 76(1):1-7. PubMed ID: 2500273
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Ballow M; Berger M; Bonilla FA; Buckley RH; Cunningham-Rundles CH; Fireman P; Kaliner M; Ochs HD; Skoda-Smith S; Sweetser MT; Taki H; Lathia C
Vox Sang; 2003 Apr; 84(3):202-10. PubMed ID: 12670369
[TBL] [Abstract][Full Text] [Related]
14. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.
Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J
J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239
[TBL] [Abstract][Full Text] [Related]
15. [Use of immunoglobulins in pediatrics].
Fischer A
Arch Fr Pediatr; 1988 Dec; 45(10):779-81. PubMed ID: 3071284
[No Abstract] [Full Text] [Related]
16. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem.
Buckley RH
J Clin Immunol; 1982 Apr; 2(2 Suppl):15S-21S. PubMed ID: 6806314
[No Abstract] [Full Text] [Related]
17. Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.
Schiff RI; Rudd C; Johnson R; Buckley RH
Clin Immunol Immunopathol; 1984 Apr; 31(1):13-23. PubMed ID: 6421523
[TBL] [Abstract][Full Text] [Related]
18. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity.
Schiff RI
Rev Infect Dis; 1986; 8 Suppl 4():S449-56. PubMed ID: 3092310
[TBL] [Abstract][Full Text] [Related]
19. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes.
Björkander J; Wadsworth C; Hanson LA
Infection; 1985; 13(3):102-10. PubMed ID: 4030106
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
